Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for zolpidem
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on zolpidem or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on zolpidem and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Zolpidem stimulant effect: Induced mania case report and systematic review of cases. Zolpidem is the most widely prescribed hypnotic agent worldwide. This easy-access drug seems to have a high addictive potential among specific populations and is now listed by the World Health Organization (WHO) as being as dangerous as benzodiazepines for dependence and abuse. Many side effects have been reported, but drug-induced mania is still extremely rare. We conducted a systematic review to study (...) the zolpidem-induced stimulation, euphoric or manic effects.MEDLINE, PsycINFO, Science Direct, and Google Scholar were searched for articles in English, French, German, Italian and Spanish published up to the 15th October 2018.Eighteen relevant cases were identified, highlighting the need for more reports; therefore, one case that occurred in our department was included. The mean usual dose was 363.31 mg (± 292.2), the minimum dose was 10 mg, the maximum dose was 2000 mg, and the mean intake duration
Zolpidem Top results for zolpidem - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for zolpidem The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence
Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis In this study, for the first time, an electro-driven microextraction method named electromembrane extraction combined with a simple high performance liquid chromatography and ultraviolet detection was developed and validated for the quantitation of zolpidem in biological samples. Parameters influencing electromembrane extraction were evaluated and optimized. The membrane consisted of 2 (...) was linear over the range of 10-1000 ng/mL for zolpidem (R2 >0.9991) with repeatability ( %RSD) between 0.3 % and 7.3 % (n = 3). The limits of detection and quantitation were 3 and 10 ng/mL, respectively. The sensitivity of HPLC-UV for the determination of zolpidem was enhanced by electromembrane extraction. Finally, the method was employed for the quantitation of zolpidem in biological samples with relative recoveries in the range of 60-79 %.
The Association Between the Use of Zolpidem and the Risk of Alzheimer`s Disease Among Older People To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people.A retrospective cohort study using data from 2001 to 2011 from the National Health Insurance Research Database.Taiwan.A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period).Zolpidem users were identified as patients who used zolpidem (...) during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped as: less than 28, 28-90, 91-180, and more than 180 cDDD).The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity
Poster 228 Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. 27672987 2019 11 20 1934-1563 8 9S 2016 Sep PM & R : the journal of injury, function, and rehabilitation PM R Poster 228 Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. S234-S235 S1934-1482(16)30545-7 10.1016/j.pmrj.2016.07.262 Bomalaski Martin N MN University of Michigan, Ann Arbor, MI, United States. Peterson Mark M Claflin Edward E eng Journal Article 2016 09 24 United States PM R
The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. The "z-drugs" zopiclone, zolpidem, eszopiclone, and zaleplon were introduced in the 1980s for the treatment of insomnia, as it was observed that the side effect profile associated with these medications were more benign than those related to the benzodiazepines. This meta-analysis set out to ascertain which domains of cognitive function, if any, were affected by the ingestion (...) of these medications. A total of 20 studies met the study inclusion criteria. Results revealed medium effect sizes for zopiclone and zolpidem on measures of verbal memory. An additional medium effect size was observed for zolpidem on attention. Finally, smaller effect sizes were observed for zolpidem speed of processing and for zopiclone on working memory. It is clear from these data that the use of a single dose of the z-drugs in healthy adults as measured in the morning following the exposure does produce
Zolpidem USE OF ZOLPIDEM IN PREGNANCY 0344 892 0909 USE OF ZOLPIDEM IN PREGNANCY (Date of issue: November 2013 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Zolpidem is a short-acting non-benzodiazepine hypnotic agent which acts (...) on benzodiazepine receptors. It is indicated in the short-term treatment of patients with debilitating insomnia, or where insomnia is causing severe distress. There are few data available concerning the use of zolpidem in human pregnancy. These data do not currently suggest an increased risk of congenital malformation but are considered too limited to state that no risk exists. Associations between in-utero zolpidem exposure and increased risks of preterm delivery and low birth weight have been reported
Intermezzo (zolpidem tartrate) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Intermezzo (zolpidem tartrate) Company: Transcept Pharmaceuticals, Inc. Application No.: 022328 Approval Date: 11/23/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created
Zolpidem and Uncontrollable Nocturnal Eating Binges Zolpidem and Uncontrollable Nocturnal Eating Binges – Clinical Correlations Search Zolpidem and Uncontrollable Nocturnal Eating Binges February 24, 2010 4 min read John Cruz Faculty peer reviewed A number of studies have shown that zolpidem ( Ambien ), the most commonly prescribed sleep-inducing medication on the market, can produce uncontrollable nocturnal eating behavior among users. Sleep related eating disorder (SRED) is characterized (...) by partial arousals from sleep to ingest food, usually within the first three hours after sleep onset, occurring one to six times per night. 1 Patients describe an “automatic” inclination to eat and an inability to return to sleep unless they eat. The foods are often high in calories and ingested in massive quantities. 2 The occurrence of zolpidem-induced nocturnal eating is probably more common than currently reported. In a New York Times article 3 entitled “Study links Ambien use to unconscious food
Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age The goal was to evaluate the hypnotic efficacy of zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day), compared with placebo, in children 6 through 17 years of age who were experiencing insomnia associated with attention-deficit/hyperactivity disorder.An 8-week, North American, multicenter, double-blind, placebo-controlled, parallel (...) of adverse events, abnormal laboratory data, vital signs, and physical examination findings. The potential for next-day residual effects also was assessed.The baseline-adjusted mean change in latency to persistent sleep at week 4 did not differ significantly between the zolpidem and placebo groups (-20.28 vs -21.27 minutes). However, differences favoring zolpidem were observed for the older age group in Clinical Global Impression scores at weeks 4 and 8. No next-day residual effects of treatment were
Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. Recent meta-analyses raising concern about risks of hypnotics suggest a need for more clarification of these risks.Because of preliminary suggestions that eszopiclone causes infections, we studied US Food and Drug Administration files on the 4 most-recently approved hypnotics, combined with published studies, to compile the risk ratios of infections for groups randomly assigned to receive hypnotics versus (...) those assigned to receive placebos in controlled trials. Parallel controlled clinical trials of eszopiclone, ramelteon, zaleplon, and zolpidem were included when data on subjects, duration of exposure, and adverse effects were available. Results of trials were combined by meta-analyses.Of 8828 participants assigned to the 4 hypnotics and 4383 participants who randomly received placebos, 606 in the hypnotics groups and 200 in the placebo groups were reported to develop some kind of infection (risk
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77) Overview | Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | Guidance | NICE Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Technology appraisal guidance [TA77] Published date: 28 April 2004 Share Save Guidance on zolpidem and zopiclone for treating insomnia in adults. The recommendations
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 77. 2004 Authors' objectives To provide guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Authors' conclusions 1.1 When, after due consideration of the use of nonpharmacological measures, hypnotic
Toward evidence-based prescribing at end of life: a comparative review of temazepam and zolpidem for the treatment of insomnia. A comparative review of temazepam and zolpidem use in managing insomnia in the hospice patient was undertaken to determine whether treatment with temazepam is a more cost-effective approach for this patient population. A MEDLINE search was conducted to identify pertinent literature, including clinical trials and reviews that involved temazepam or zolpidem. Published (...) data was used as background information and provided in the discussion. This retrospective analysis, conducted from June 2002 through November 2002, focused on the prescribing patterns of temazepam and zolpidem in our hospice practice setting. We examined the reasons for discontinuation of each agent, along with the frequency of therapeutic change from temazepam to zolpidem. The top 10 ICD-9 codes associated with each treatment modality were investigated to determine any prescribing patterns
Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data Hajak G, Muller W E, Wittchen H U, Pittrow D, Kirch W CRD summary (...) This review of case reports of the abuse and dependence potential of zolpidem and zopiclone concluded that they are relatively safe. Patients with a history of abuse or dependence, or with psychiatric disease, are at increased risk of abuse or dependence. Methodological and reporting limitations mean that this review alone cannot provide robust evidence of the safety of these drugs. Authors' objectives To review the world literature for cases of dependence of zolpidem and zopiclone in order to identify
Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. To evaluate the efficacy of benzodiazepines and zolpidem tartrate in chronic insomnia based on a quantitative review of literature.Articles from 1966 to 1996 were identified using MEDLINE, by a manual review of relevant journals, and from bibliographies of identified articles.Studies using randomized, double-blind, placebo-controlled, parallel or crossover designs with benzodiazepines or zolpidem in adults (...) to placebo. A combined test of effect sizes was performed on the subset of studies that reported effect size information to determine the magnitude of medication effect.A homogeneous sample of studies summarized 1894 patients treated for a median duration of 7 days. The combined test of P values demonstrated that medication was superior to placebo in all 4 outcome measures. Treatment response was moderate in magnitude by the combined test of effect sizes.Benzodiazepines and zolpidem produced reliable
Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy Nowell P D, Mazumdar S, Buysse D J, Dew M A, Reynolds C F, Kupfer D J Authors' objectives To assess the efficacy of benzodiazepines and zolpidem for chronic insomnia. Searching MEDLINE was searched from 1966 to 1996. Current (...) but data were extracted only for the first treatment period. Specific interventions included in the review Flurazepam, estazolam, zolpidem, triazolam, quazepam, temazepam and lorazepam. These were all compared with placebo. The median duration of treatment was 7 days (range: 4 to 35). Participants included in the review People with chronic primary insomnia, in whom psychiatric and medical conditions had been ruled out as causes of insomnia. The particpants' age ranged from 18 to 65 years old